Category Archives: Human Genetic Engineering

Human Genetic Engineering PSU Video
Human Genetic EngineeringFrom:stevie54271Views:59 1ratingsTime:14:07More inScience Technology

Read the original here:
Human Genetic Engineering PSU Video - Video

Bruce Lipton - New Health Paradigm
upliftfestival.com UPLIFT 2012 is thrilled to bring Bruce Lipton to Byron Bay! Bruce H. Lipton, PhD is an internationally recognized leader in bridging science and spirit. Stem cell biologist, bestselling author of The Biology of Belief and recipient of the 2009 Goi Peace Award, he has been a guest speaker on hundreds of TV and radio shows, as well as keynote presenter for national and international conferences. Dr. Lipton began his scientific career as a cell biologist. He received his Ph.D. Degree from the University of Virginia at Charlottesville before joining the Department of Anatomy at the University of Wisconsin #39;s School of Medicine in 1973. Dr. Lipton #39;s research on muscular dystrophy, studies employing cloned human stem cells, focused upon the molecular mechanisms controlling cell behavior. An experimental tissue transplantation technique developed by Dr. Lipton and colleague Dr. Ed Schultz and published in the journal Science was subsequently employed as a novel form of human genetic engineering. In 1982, Dr. Lipton began examining the principles of quantum physics and how they might be integrated into his understanding of the cell #39;s information processing systems. He produced breakthrough studies on the cell membrane, which revealed that this outer layer of the cell was an organic homologue of a computer chip, the cell #39;s equivalent of a brain. His research at Stanford University #39;s School of Medicine, between 1987 and 1992, revealed that the environment ...From:UPLIFTfestivalTVViews:35 0ratingsTime:02:48More inPeople Blogs

Read the original post:
Bruce Lipton - New Health Paradigm - Video

ST. LOUIS, Oct. 16, 2012 /PRNewswire/ --Sigma-Aldrich Corporation (SIAL) today announced that Sigma Advanced Genetic Engineering (SAGE) Labs, an initiative of Sigma Life Science, and Ekam Imaging, Inc. have partnered to develop a suite of preclinical services based on the advanced translational power of genetically engineered rat models from SAGE Labs and Ekam's expertise in functional magnetic resonance imaging (fMRI) technology. For more information on SAGE Labs, visit http://www.sageresearchmodels.com.

Unlike the fMRI studies currently performed in drug development that require anesthetized, unconscious animals, Ekam Imaging's fMRI translational technology produces detailed maps of a conscious animal's brain activity, a state that much better represents the human condition.

"The rat models created by SAGE Labs have been genetically modified to reflect patient-relevant mutations and exhibit highly relevant, robust phenotypes. The combination of these rats with Ekam's imaging platform presents a transformative opportunity for translational neuroscience programs. Ultimately, these types of studies will lead to better drugs targeting neurodegenerative diseases such as Parkinson's and Alzheimer's diseases," said Edward Weinstein, Ph.D., Director of SAGE Labs.

"Probing the brain functions of a conscious animal, specifically in rats which are prized by the neuroscience community for intelligence and complex social behaviors, produces data that is much more representative of a potential therapy's effects on human processes," said Mark Nedelman, MS, MBA, President and CEO of Ekam Imaging.

Nedelman's company is currently producing a detailed map of neural activity in SAGE Lab's Pink1 gene knockout rat, which SAGE Labs generated for The Michael J. Fox Foundation to model Parkinson's disease. The Pink1 gene knockout rat exhibits delayed-onset motor deficits, a key phenotype of Parkinson's disease in humans.

Sigma and Ekam plan to publicly launch services specific to SAGE Labs' neuroscience rat models in early 2013.

Cautionary Statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "more precise," "unambiguously," "curtail," "rapidly" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that preclincal imaging assays or related services will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with preclinical imaging assays or related services could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 38 countries and has nearly 9,100 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich, please visit its website at http://www.sigma-aldrich.com.

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co, LLC registered in the US and other countries. SAGE is a registered trademark of Sigma-Aldrich Co. LLC.

Visit link:
SAGE® Labs, Ekam Imaging, Inc. Partner to Develop Preclinical Imaging Assays to Screen Therapies of Neurodegenerative ...

ScienceDaily (Oct. 11, 2012) Scientists have observed the neurological mechanism behind temperature-dependent -- febrile -- seizures by genetically engineering fruit flies to harbor a mutation analogous to one that causes epileptic seizures in people. In addition to contributing the insight on epilepsy, their new study also highlights the first use of genetic engineering to swap a human genetic disease mutation into a directly analogous gene in a fly.

In a newly reported set of experiments that show the value of a particularly precise but difficult genetic engineering technique, researchers at Brown University and the University of California-Irvine have created a Drosophila fruit fly model of epilepsy to discern the mechanism by which temperature-dependent seizures happen.

The researchers used a technique called homologous recombination -- a more precise and sophisticated technique than transgenic gene engineering -- to give flies a disease-causing mutation that is a direct analogue of the mutation that leads to febrile epileptic seizures in humans. They observed the temperature-dependent seizures in whole flies and also observed the process in their brains. What they discovered is that the mutation leads to a breakdown in the ability of certain cells that normally inhibit brain overactivity to properly regulate their electrochemical behavior.

In addition to providing insight into the neurology of febrile seizures, said Robert Reenan, professor of biology at Brown and a co-corresponding author of the paper in the Journal of Neuroscience, the study establishes

"This is the first time anyone has introduced a human disease-causing mutation overtly into the same gene that flies possess," Reenan said.

Engineering seizures

Homologous recombination (HR) starts with the transgenic technique of harnessing a transposable element (jumping gene) to insert a specially mutated gene just anywhere into the fly's DNA, but then goes beyond that to ultimately place the mutated gene into exactly the same position as the natural gene on the X chromosome. HR does this by outfitting the gene to be handled by the cell's own DNA repair mechanisms, essentially tricking the cell into putting the mutant copy into exactly the right place. Reenan's success with the technique allowed him to win a special grant from the National Institutes of Health last year.

The new paper is a result of that grant and Reenan's collaboration with neurobiologist Diane O'Dowd at UC-Irvine. Reenan and undergraduate Jeff Gilligan used HR to insert a mutated version of the para gene in fruit flies that is a direct parallel of the mutation in the human gene SCN1A that causes febrile seizures in people.

When the researchers placed flies in tubes and bathed the tubes in 104-degree F water, the mutant fruit flies had seizures after 20 seconds in which their legs would begin twitching followed by wing flapping, abdominal curling, and an inability to remain standing. After that, they remained motionless for as long as half an hour before recovering. Unaltered flies, meanwhile, exhibited no temperature-dependent seizures.

The researchers also found that seizure susceptibility was dose-dependent. Female flies with mutant strains of both copies of the para gene (females have two copies of the X chromosome) were the most susceptible to seizures. Those in whom only one copy of the gene was a mutant were less likely than those with two to seize, but more likely than the controls.

Continue reading here:
Engineered flies spill secret of seizures

ScienceDaily (Oct. 10, 2012) Huntington's disease (HD) is an inherited genetic disorder caused by the multiple repetition of a DNA sequence (the nucleotides CAG) in the gene encoding a protein called "Huntingtin". People who do not suffer from the disease have this sequence repeated 10 to 29 times. But in an affected person, the triplet is present more than 35 times.

Huntingtin protein can be found in various tissues of the human body and is essential for the development and survival of neurons in adults. When the mutant gene is present, an aberrant form of the Hungtingtin protein is produced, causing the symptoms of the disease: involuntary movements, changes in behavior and dementia, among others. Although there are several promising studies, there is currently no cure for HD. There are only palliative treatments of symptoms, and Huntington's patients die about 15 years after the symptoms onset.

Unlike other neurodegenerative diseases (such as Alzheimer or Parkinson), only a single gene is responsible for HD (i.e. the disorders is monogenic), and a therapy based on the inhibition of the gene, will open new perspectives of research for the development of a treatment.

A recently developed tool by scientists around the world is based on the modification of proteins that are found naturally in all living beings. These proteins are called Zinc Finger proteins, and can recognize and bind to specific DNA sequences. This enables the regulation of those genes to which they are attached.

A study conducted by researchers of the Centre for Genomic Regulation (CRG) in Barcelona provides positive results reducing the chromosomal expression of the mutant gene, which would prevent the development of disease. The research is published in Early Edition by the journal Proceedings of the National Academy of Sciences (PNAS).

"We designed specific ZFP that recognize and specifically bind to more than 35 repetitions of CAG triplet, preventing the expression of the gene containing these repeats and reducing the production of the mutant Huntingtin protein. When applying this treatment to a transgenic mouse model carrying the human mutant Huntingtin gene, we observed a delayed onset of the symptoms, "says Mireia Garriga-Canut, first author of the study and researcher at the Gene Network Engineering group at the CRG. Another co-author of the study, Carmen Agustn Pavn, adds that "the next step is to optimize the design for an effective and durable treatment for patients. This would pave the way to find a therapy for Huntington's disease".

The research was funded by the FP7 program of the European Commission and the Ministry of Science and Innovation of Spain.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

More:
Zinc fingers: A new tool in the fight against Huntington's disease

ScienceDaily (Oct. 9, 2012) Using genes as interchangeable parts, synthetic biologists design cellular circuits that can perform new functions, such as sensing environmental conditions. However, the complexity that can be achieved in such circuits has been limited by a critical bottleneck: the difficulty in assembling genetic components that don't interfere with each other.

Unlike electronic circuits on a silicon chip, biological circuits inside a cell cannot be physically isolated from one another. "The cell is sort of a burrito. It has everything mixed together," says Christopher Voigt, an associate professor of biological engineering at MIT.

Because all the cellular machinery for reading genes and synthesizing proteins is jumbled together, researchers have to be careful that proteins that control one part of their synthetic circuit don't hinder other parts of the circuit.

Voigt and his students have now developed circuit components that don't interfere with one another, allowing them to produce the most complex synthetic circuit ever built. The circuit, described in the Oct. 7 issue of Nature, integrates four sensors for different molecules. Such circuits could be used in cells to precisely monitor their environments and respond appropriately.

"It's incredibly complex, stitching together all these pieces," says Voigt, who is co-director of the Synthetic Biology Center at MIT. Larger circuits would require computer programs that Voigt and his students are now developing, which should allow them to combine hundreds of circuits in new and useful ways.

Lead author of the paper is former MIT postdoc Tae Seok Moon, now an assistant professor of energy, environmental and chemical engineering at Washington University in St. Louis. Other authors are MIT postdocs Chunbo Lou and Brynne Stanton, and Alvin Tamsir, a graduate student at the University of California at San Francisco.

Expanding the possibilities

Previously, Voigt has designed bacteria that can respond to light and capture photographic images, and others that can detect low oxygen levels and high cell density -- both conditions often found in tumors. However, no matter the end result, most of his projects, and those of other synthetic biologists, use a small handful of known genetic parts. "We were just repackaging the same circuits over and over again," Voigt says.

To expand the number of possible circuits, the researchers needed components that would not interfere with each other. They started out by studying the bacterium that causes salmonella, which has a cellular pathway that controls the injection of proteins into human cells. "It's a very tightly regulated circuit, which is what makes it a good synthetic circuit," Voigt says.

The pathway consists of three components: an activator, a promoter and a chaperone. A promoter is a region of DNA where proteins bind to initiate transcription of a gene. An activator is one such protein. Some activators also require a chaperone protein before they can bind to DNA to initiate transcription.

View post:
Most complex synthetic biology circuit yet: New sensor could be used to program cells to precisely monitor their ...